1.
Expert Opin Biol Ther
; 7(4): 509-19, 2007 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17373902
RESUMO
Colon and rectal cancer remain the second most common cause of cancer death in the US. Advances in the past 10 years have resulted in improved outcomes for patients. In addition to newer chemotherapeutics agents, the so-called 'targeted' or 'biological' therapies have improved survival in patients with metastatic disease. This review aims to summarize the mechanistic basis for the usefulness of these agents, the key clinical trials demonstrating their efficacy, and the studies now initiated with the hope of further incorporating their use in treating colon and rectal cancer.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Terapia Biológica/métodos , Neoplasias Colorretais/tratamento farmacológico , Fluoruracila/uso terapêutico , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Anticorpos Monoclonais Humanizados , Bevacizumab , Terapia Biológica/tendências , Cetuximab , Quimioterapia Adjuvante , Humanos , Ftalazinas/uso terapêutico , Inibidores de Proteínas Quinases/uso terapêutico , Piridinas/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Clin Adv Hematol Oncol
; 2(2): 122; discussion 122-4, 2004 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16163173